PASG News and Press, Passage Bio Inc. From 03/04/25

Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 ...

BBB Foods Inc. Class A (TBBB) is expected to report $0.02 for Q4 2024 Beamr Imaging Ltd. (BMR) is expected to report for quarter end 2024-12-31 Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.5 for Q4 2024 Henkel AG & Co. KGAA ADR (HENKY) is expected to report ...

PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than Dose 1, in subsequent FTD-GRN and FTD-C9orf72 patients to allow for dos...